1[3]Tsujitani S, Oka S, Suzuki K, et al. Prognosis factors in patients with advanced gastric cancer treated by noncurative resection: A multivariate analysis [J]. Hepatogastroenterology, 2001, 48:1504 - 1508.
2[4]Hanazaki K, Sodeyama H, Mochizuki Y, et al. Palliative gastrectomy for advanced gastric cancer [J]. Hepatogastroenterology, 2001, 48:285 - 289.
3[5]Hoff PM, Fuchs CS. The experience with oxaliplatin in the treatment of upper gastrointestinal carcinomas [J]. Semin Oncol,2003, 30: 54.
4[7]Louvet C, Andre T, Tigaudj M, et al. Phase Ⅱ study of oxaliplatin, fluorouracil and folinc acid in locally advanced or metastatic gastric cancer patients [J]. Clin Oncol, 2002, 20(23): 4543.
5De Gramont A, Krulik M, Cady J, et al. High-dose folinic acid and 5-fluorouracil bolus and continuous infusion in advanced colorectal cancer.Eur J Cancer Clin Oncol, 1988, 24:1499-1503.
6Ajani JA. Current status of therapy for advanced gastric carcinoma.Oncology, 1998, 12:99-102.
7Raymond E, Charley SG, Taamma A, et al. Oxaliplatin: a review of preclinical and clinical studies. Ann Oncol, 1998, 9:1053-1071.
8De Gramont A, Figer A, Seymonr M, et al. Leucovorin and fluorouracil with or without oxaliplatin as frist-line treatment in advanced colorectal cancer. J Clin Oncol, 2000,18:2938-2947.
9De Gramont A, Bosset JF, Milan C, et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly highdose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer : a French intergroup study. J Clin Oncol,1997, 15:808-815.
10Mac Donald J S . Chemotherapy of carcinoma of the stomach[J].Cancer Treat Rev, 1993,19( 1 ): 29.
9Jing-Ting Jiang, Chang-Ping Wu, Lu-Jun Chen, Xiao Zheng, Department of Tumor Biological Treatment, Third Affiliated Hospital of Soochow University, Changzhou 213003, Jiangsu Province, China Yi-Bei Zhu, Jing Sun, Xue-Guang Zhang, Key Laboratory of Stem Cell of Jiangsu Province, Institute of Biotechnology, Key Laboratory of Clinical Immunology of Jiangsu Province, Soochow University, Suzhou 215123, Jiangsu Province, China Yue-Ping Shen, Wen-Xiang Wei, Department of Medicine, Soochow University, Suzhou 215123, Jiangsu Province, China Bin-Feng Lu, Department of Immunology, University of Pitts- burgh School of Medicine, Pittsburgh, PA 15261, United States.Increasing the frequency of CIK cells adoptive immunotherapy may decrease risk of death in gastric cancer patients[J].World Journal of Gastroenterology,2010,16(48):6155-6162. 被引量：82
8Kunisaki C, Shimada H, Akiyama H, et al. Survival benefit of palliative gastrectomy in advanced incurable gastric cancer[J].Anticancer Res, 2003, 23 (32): 1853-- 1858.
9Fuchs C S, Marshall J, Barrueco J. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first --line treament of metastatic colorectal cancer: updated results from the BICC C study[J].J ClinOncol,2008,26(4):689--690.
10Goldberg R M, Sargent D J, Morton R F, et al. NCCTG Study N69741 : leveraging learning from an NCI Cooperative Group phase III trial[J]. Oncologist, 2009,14 (10) : 970 -- 978.
